RxDoctor Payments DataLook up a doctor →

Deborah Price, MD

Nephrology · Jacksonville, FLNPI 1972542140

Payments from drug & device makers

$320,839in general payments, 2019–2025

Across 419 payments — averaging $765.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Akebia Therapeutics Inc$253K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$57K
  • Vifor Pharma, Inc.$4K
  • AstraZeneca$1K
  • Amgen$709
  • Johnson & Johnson$467
  • plus $4K from 35 others

What the payments were for

  • Speaking & faculty fees$7,51549%
  • Travel & lodging$2482%
  • Food & beverage$7,28947%
  • Education$3012%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$320,839 in reported general payments places this provider in the 90th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$95,977
Medicare patients
338
Services billed
1,139

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VeltassaPatiromer Calcium Sorbitex49$44,200
FarxigaDapagliflozin Propanediol43$38,474
LokelmaSodium Zirconium Cyclosilicate28$12,239
JardianceEmpagliflozin14$11,351
Nifedipine ErNifedipine50$1,371
Olmesartan Medoxomil15$1,295
Hydralazine Hcl63$978
Losartan Potassium85$974
Bumetanide26$970
Carvedilol68$914
Valsartan25$776
Amlodipine Besylate113$709
Metoprolol Succinate24$661
Potassium Chloride32$636
Cinacalcet Hcl13$585

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$1,146$50,71371 claims
Boehringer IngelheimJardiance$76$11,35114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 756 nephrology providers in Florida.

Other nephrology in Jacksonville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →